Oncolys BioPharma Inc.
 

March, 2004 Incorporated as Oncolys BioPharma in Tokyo, Japan
May, 2004   First round of financing
August, 2004   Second round of financing
October, 2004   Third round of financing
December, 2004   New HQ established in Roppongi-2chome, Tokyo, Japan
March, 2005   Annual stockholders meeting
April 2005 Trade name "Telomelysin" registered
May 2005 Telomescan was adopted by NEDO's grant in 2005 titled, "Project for R&D on Molecule Imaging Equipment. R&D of Molecule Imaging Equipment for Malignant Tumor Therapy Support."
*NEDO: New Energy and Industrial Technology Development Organization
December 2005 Trade name "Oncolys" registered
February 2006 Fourth round of allocating new shares to a third party
March 2006 Filed an investigational new drug (IND) application for Telomelysin® with U.S. Food and Drug Administration (FDA)
March 2006 Fifth round of allocating shares to a third company
May 2006 Trade name "Telomescan" registered
June 2006 Concluded a joint development agreement with Sysmex Corporation to develop Telomescan®
June 2006 Concluded an exclusive license agreement with Yale University, US, granting Oncolys global exclusive license agreement of the novel anti-HIV agent, FESTINAVIR®
July 2006 Headquarters moved to 3-chome, Roppongi, Minato-ku, Tokyo
September 2006 Sixth round of financing
October 2006 Opened the Kyoto Research Center
October 2006 Seventh round of financing
October 2006 Obtained a patent for Telomelysin® in Japan (Patent No. 3867968)
October 2006 Initiated a phase I clinical trial with Telomelysin® in the US
September 2007 Award by Minister of Education, Culture, Sports, Science and Technology, "The 5th Japan Bio-Venture Award"
November 2007 Opened the Kobe Research Center
March 2008 Signed strategic alliance and license agreement with Medigen Biotechnology Corp. for Telomellysin®
March 2008 Signed strategic alliance and license agreement with Tacere Therapeutics, Inc. for OBP-701(TT-033)
March 2008 Eighth round of financing
March 2008 Filed an investigational new drug (IND) application for FESTINAVIR® Food and Drug Administration (FDA)
April 2008 Received IND approval from the US Food and Drug Administration (FDA) for FESTINAVIR® to initiate phase-I clinical trial in the United States.

| HOME |
Copyright (c)2004-2005, Oncolys BioPharma Inc. All rights reserved.